



Benign lesions in the non - cirrhotic liver

Value of hepatobiliary agents

Călin Vainak Adriana | Regional Institute of Gastroenterology and Hepatology "Octavian Fodor"

—

Key discussion points

- 1. Role of hepatobiliary contrast media in the diagnosis of benign liver lesions;**
- 2. Imaging features of benign liver lesions;**
- 3. Management of incidental liver lesions.**

—

MRI principles

- Multiparametric approach, due to multitude of sequences: T1 IP/OOP (fat), T2, DWI, MRCP (when needed), CE-MRI;
- Non-invasive tool;
- Contrast agents containing Gd shorten relaxation on T1 sequences (either extracellular or hepatobiliary);
- Detection of focal lesions;
- Assessment of the liver background;
- Biliary pathology;

—

Benign liver lesions

- Are frequently encountered in clinical practice;
- They can arise from epithelial cells (hepatocytes and biliary cells) or non epithelial cells (mesenchymal cells);
- Contrast-enhanced MRI is the best method to characterize liver lesions;
- Advanced techniques, such as DWI and hepatobiliary contrast can improve confidence;
- Some lesions may be confidently diagnosed with MRI, making biopsy unnecessary;

—

Hepatobiliary contrast agents

- **Gadoxetic acid (Gd – EOB – DTPA - Primovist®; Bayer – Schering, Berling, Germany);**
- 0.025mmol/kg;
- Absorbed by hepatocytes via organic anion transporting polypeptides (OATP 1) transporter and excreted by multidrug resistance protein 2 (MRP 2);
- A fraction is excreted in the biliary canaliculi – 50%;
- Transitional phase (3-5 min) and hepatobiliary phase (20 min);
- Enhancement pattern of lesions depending on the content of functioning hepatocytes;

- **Gadobenate dimeglumine (Gd-BOPTA - MultiHance®; Bracco, Milan, Italy);**
- 0.1mmol/kg;
- 2 fold T1 relaxivity compared to Gadoxetic acid;
- Only 2-4% is excreted via biliary canaliculi;
- HBP at **60-90 min.**

—

MRI contrast agent

Category	Molecule	Structure	Ioniity	Relaxivity	Recommended dose (mmol/kg)	Excretion
ECAs	Gadoterate meglumine (Dotarem)	Macrocyclic	Ionic	Standard	0.1	Renal
ECAs	Gadobutrol (Gadavist)	Macrocyclic	Non-ionic	Standard	0.1	Renal
ECAs	Gadoteridol (Prohance)	Macrocyclic	Non-ionic	Standard	0.1	Renal
ECAs	Gadopentetate dimeglumine (Magnevist)	Linear	Ionic	Standard	0.1	Renal
ECAs	Gadoversetamide (OptiMark)	Linear	Non-ionic	Standard	0.1	Renal
ECAs	Gadodiamide (Omniscan)	Linear	Non-ionic	Standard	0.1	Renal
HBA	Gd-EOB-DTPA (Eovist/Primovist)	Linear	Ionic	High	0.025	50% renal, 50% biliary
HBA	Gd-BOPTA (MultiHance)	Linear	Ionic	High	0.1	5% biliary, 95% renal
BPA	Gadofosveset trisodium (Ablavar)	Linear	Ionic	High	0.03	Renal

ECAs: Extracellular agents; HBA: Hepatobiliary agents; BPA: Blood pool agents.

Gatti M, Maino C, Tore D, Carisio A, Darvizeh F, Tricarico E, Inchingolo R, Ippolito D, Faletti R. Benign focal liver lesions: The role of magnetic resonance imaging. *World J Hepatol.* 2022 May 27;14(5):923-943. doi: 10.4254/wjh.v14.i5.923. PMID: 35721295; PMCID: PMC9157713.



—


MRI protocol

- T1, T2, DWI, multiphase contrast enhanced T1 sequences
- T2 and DWI may be acquired after contrast injection, after the TP (may improve lesion-liver CNR, due to shortened T2 relaxation time)
- Diffusion coefficients and shear liver stiffness may also be evaluated after contrast injection
- HBP usually at 20 min/60-90 min – **HYPER** parenchyma, **HYPO** vessels, **HYPO** kidneys, contrast excretion via bile ducts
- Increased flip angle (30-35);


—

Different flip angles

Flip angle = 10



Flip angle = 30



—

Classification of benign liver lesions

Gatti M, Maino C, Tore D, Carisio A, Darvizeh F, Tricarico E, Inchingolo R, Ippolito D, Faletti R. Benign focal liver lesions: The role of magnetic resonance imaging. *World J Hepatol.* 2022 May 27;14(5):923-943. doi: 10.4254/wjh.v14.i5.923. PMID: 35721295; PMCID: PMC9157713.

Epithelial tumors (hepatocellular and biliary)	Mesenchymal tumors	Pseudotumor
Hepatocellular adenoma	Hemangioma	Focal fatty infiltration
Focal nodular hyperplasia	Lymphangioma	Infection (liver abscess, <i>Echinococcus granulosus</i>)
Biliary cystadenoma	Solitary fibrous tumor	Inflammatory disorder of the liver (pseudotumor, sarcoidosis)
Biliary hamartoma (von Meyenburg Complex)	Mesenchymal hamartoma	

—


Hepatocellular adenoma (HCA)

- Occurs mostly in women between 15-45 years;
- Strongly associated with oral contraceptive consumption (OCP), but also with anabolic androgenic steroids, glycogen storage disease, obesity, diabetes, Fanconi's anemia, FAP, beta thalassemia, tyrosinemia;
- Composed of hepatocytes;
- Perfused by peripheral arterial vessels – **high vascular nature**;
- Adenomatosis >10 lesions;
- May undergo hemorrhage or malignant transformation;

—


Type 1: HNF-1 α HCA

- 2nd most common subtype (30-35%);
- Almost only in women with a history of OCP;
- Lowest risk of malignant transformation;
- **HYPER/ISO**intense on T1, **ISO/HYPER**intense on T2;
- NO restricted diffusion;
- **FAT** content – signal loss on T1 OOP compared to T1 IP – 86,7% sensitivity and 100% specificity;
- **HYPER** enhancement in the arterial phase (AP), which doesn't persist in the portal venous phase (PVP).




DWI + ADC

F, 31, HNF-1 α adenoma



T1 OOP + IP



T2

T1+C, hepatobiliary phase

—


Type 2: I-HCA

- Most frequent subtype (40-50%);
- Young women with OCP use, metabolic syndrome, obesity;
- Highest risk of bleeding (30%);
- Malignant transformation: 5-10%;
- Intralesional hemorrhage: acute (**HYPER T1**)/chronic (**HYPO T1+T2**);
- Atoll sign: heterogeneous **HYPER**intense on T2, particularly in the periphery;
- **HYPER**enhancement in the AP, persistence in the PVP, DP, **HYPO** in the HBP;

—

Type 3: β catenin activated HCA


- 10-15% of HCAs
- Continuous activation of the β -catenin protein, resulting in uncontrolled growth of hepatocytes
- More common in **men**
- Associated with anabolic androgenic steroids, glycogen storage disease, familial adenomatous polyposis
- Highest risk of **malignant transformation**
- May retain HB contrast agents and may be **HYP**ERintense in the HBP



T2

DWI + ADC

18, M, glycogenosis type
B, β -catenin adenoma



T1 + C, arterial

T1+ C, venous

T1+ C, transitional

T1+ C, hepatobiliary

—

Type 3: unclassified HCAs

- 10% of HCAs;
- Adenomas, but with no particular characteristics, including genetics, clinical appearance or imaging features.



—


FNH

- Second most common benign liver lesion (8-9%);
- Predilection for female patients, 3rd-5th decade;
- No relation to OCP;
- Hepatocytes + fibrous septa + central scar;
- Hypervascular due to rich capillaries;
- Associated with other vascular conditions (HA, arteriovenous malformations, shunts etc);

- **ISO**intense on T1 and T2 due to the presence of hepatocytes;
- Homogeneous and strong contrast enhancement in the AP, excepting the central scar;
- **ISO**intense in the PV phase, while the scar remains slightly hypointense;
- **ISO- to HYPER**intense in the HBP, scar mainly HYPO, sometimes HYPER;
- When atypical difficult to distinguish from HCA;

- Central scar better depicted on MRI (HYPER T2; DDx in HCC: HYPO);
- Extracellular contrast agents and CT: scar enhances in the DP;
- Gd-BOPTA - MultiHance®; Bracco, Milan, Italy – scar is **HYPER**intense in the LP;
- Gadoxetic acid (Gd – EOB – DTPA - Primovist®; Bayer – Schering, Berling, Germany) - scar is always **HYPO**intense, due to the overlap of the late PV and the HBP (everything not containing hepatocytes will be **HYPO**, including fibrous tissue).

FNH - 35, F




T1 pre contrast

DWI

ADC

T2




T1+C, arterial

T1+C, venous


T1+C, transitional

T1+C, hepatobiliary


FNH- 34, M




DWI+ADC




T1 pre contrast




T1+C, arterial



T1+C, venous



T1+C, transitional



T1+C, hepatobiliary

Atypical:


- No central scar;
- Large central scar;
- Intralesional fat;
- Pseudocapsule;
- Sinusoidal distension.

—

Biliary cystadenoma

- Rare, benign hepatic tumor
- Origin from the intrahepatic bile ducts
- Almost always in **women**
- Predilection for the **right hepatic lobe**
- Fluid-containing lesion with septa, various signal intensity depending on proteinaceous content
- Risk of malignancy: nodular growth, hemorrhage, vascularized septa

Biliary cystadenoma- 74, F



DWI + ADC


T2

—



Biliary hamartomas (von Meyenburg complex)

- Rare biliary malformations
- Mostly occur in women (~48 years)
- More common in chronic liver disease
- Small, infracentimetric, subcapsular
- **HYP**Ointense on T1, **HYPER**intense on T2
- May present mural nodules with PVP enhancement
- MRCP: "**starry sky**" appearance, with no communication with bile ducts, HBP may demonstrate the lack of connection to bile ducts

Biliary hamartomas (von Meyenburg complex)



44, F, T2 axial




66, M, T2 Haste Coronal, MIP reformat

—


FNH-like lesions

- Histologically and radiologically identical, but in an abnormal liver
- Fontan – associated liver disease (surgical technique for complex cardiac disease), Budd – Chiari syndrome, abnormal hepatic venous flow (congenital absence of PV, cavernoma, Osler-Weber-Rendu, chemotherapy)
- No risk of malignant transformation
- DDx: HCC (some of the conditions are risk factors for HCC)



FNH – like lesions after chemotherapy – 43, M




T2




DWI+ADC



T1+C arterial




T1+C venous




T1+C delayed phase


FNH – like in Portal Vein Thrombosis – 32, F



T1+C, arterial subtraction



T1+C venous




T1+C hepatobiliary

—


Nodular regenerative hyperplasia

- Multiple regenerative nodular lesions, ~1mm diameter
- Associated with impaired venous flow
- Hematologic (lymphoproliferative, myeloproliferative, immunodeficiency, HIV), autoimmune, vascular (congenital absence of PV, Budd-Chiari syndrome, PV thrombosis), medications
- DD cirrhosis: no fibrosis


Nodular regenerative hyperplasia – Budd – Chiari syndrome, 52, F



T₁+C, arterial



T₁+C venous



T₁+C transitional



T₁+C hepatobiliary

—

Hemangioma (HA)

- Most common benign liver lesion (20%), incidental findings
- More common in women
- Small: 1-2 cm, typical: 2-10cm, giant: >10cm
- Cavernous vascular spaces, lined by endothelium + fibrous stroma
- 3 different subtypes
- Most commonly diagnosed with extracellular contrast agents, NOT an indication for hepatobiliary contrast agents!

Cavernous HA

- Most common type
- <3cm, large vascular spaces
- Homogeneous **HYPER** T2, may contain a hypointense hyalinized/thrombosed area or calcifications (diffuse hypointensity)
- DWI – **high signal on b0**, decrease at higher b values, sometimes residual hyperintensity on high b values = "**T2 shine through**"
- ADC higher than surrounding liver
- Peripheral nodular enhancement, centripetal and progressive filling on PVP and DP, "**blood-pool**" sign – similar to aorta in all phases
- No hepatocytes = > **HYPO**intensity on HBP


Capillary HA

- 16% of all HA
- Mostly <1cm
- **HYPER T2** and **HYPO T1**
- Steatosis – **HYPER T1** on OOP, due to peritumoral fatty sparing
- Early enhancement, similar to the aorta
- Transient perilesional enhancement
- Persistence of contrast enhancement in DP, compared to metastases (hypointensity)


Sclerosed/hyalinized HA

- Presence of fibrosis
- Slight HYPER T2 signal
- Slow and heterogeneous enhancement in the later phases
- Late centripetal filling may be seen


Hemangioma – hepatobiliary contrast, 36, M




T2




DWI+ADC




T1+C, arterial



T1+C, venous




T1+C, transitional




T1+C, hepatobiliary


Hemangioma – extracellular contrast



T1+C, arterial




T1+C, venous




T1+C, delayed phase


Flash filling hemangioma



T1+C, arterial



T1+C, venous




T1+C, delayed phase

Angiomyolipoma

- Arteries + fat + smooth muscle cells
- 4 subtypes: mixed, lipomatous, myomatous, angiomatous
- Associated with Tuberous Sclerosis
- Fat containing: **HYPER T1**, signal loss on **T1 OOP**
- Low fat content: **HYPER T2, HYPO T1**, heterogeneous contrast enhancement, difficult to distinguish from HCC
- **Higher ADC** values than HCC with fat component
- No hepatocytes – **HYPO**intensity on HBP

Angiomyolipoma in a patient with tuberous sclerosis



T1 Out-of-Phase

T1+C venous

T1+C, hepatobiliary



Case courtesy of Dr. Caraianni Cosmin

—

Lymphangioma


- Rare benign tumor
- Rarely seen in liver, mostly in lymphangiomatosis
- Women, >30 years
- Mixed – solid and cystic mass, septa, nodules
- Intermediate signal due to intralesional bleeding

—

Focal fatty infiltration


- **Signal drop** on T1 OOP in comparison to T1 IP
- **HYPO**intensity on T2
- Reduced number of functioning hepatocytes – **HYPO**attenuating
- Wedge-shaped
- Lack of mass effect
- Round – DDx with fat-containing liver masses
- Fat spared areas – no signal drop, **HYPER**attenuating on HBP, due to normally functioning hepatocytes

Focal fatty infiltration – 46, F



DWI+ADC

T1 Opposed Phase + In Phase



T1+C, arterial

T1+C, venous

T1+C, transitional

T1+C, hepatobiliary


—

Liver abscess


- MRI best depicts lesions
- **ISO/HYPER** T1 – hemorrhage, proteinaceous content, no signal drop
- Edema/peripheral inflammation seen on T2
- High restricted diffusion, **centrally** (DDx: tumor, more peripherally)
- Peripheral rim enhancement in PVP and TP
- Periphery is **HYPO/ISO** in the HBP, due to edema in the surrounding functioning hepatocytes
- Main **DDx: metastases**

Liver abscess – 74, M


T2 axial



T1+C, venous



Liver abscess versus tumor



55, M, abscess

74, M, tumor



—

Echinococcosis


- **Cystic** (*E. granulosus*) or **alveolar** (*E. multilocularis*)
- From sheep and pigs/fox
- Cystic lesion, varying size, two layers (germinal layer and outer layer)
- First stage: simple cyst, peripheral enhancement in PVP
- Daughter cysts: honeycombing appearance
- Possible rupture into bile ducts
- End stage: solid component and calcifications

Hydatid cyst, F, 33

SPACE sequence




T2




T1+C, HBP

Hydatid cyst with daughter cysts – 49, F




T1+C HBP



T2 coronal


T1+C venous

Hydatid cyst with floating membrane – 24, M




T2 coronal

Diffuse alveolar hydatidosis – 42, M



T2 axial + coronal

T1+C HBP



DWI+ADC

—

Management of benign liver lesions

Suspected hepatocellular adenoma	
7.	Oral contraceptives, hormone-containing IUDs, and anabolic steroids are to be avoided in patients with hepatocellular adenoma (strong recommendation, moderate quality of evidence).
8.	Obtaining a biopsy should be reserved for cases in which imaging is inconclusive and biopsy is deemed necessary to make treatment decisions (strong recommendation, low quality of evidence).
9.	Pregnancy is not generally contraindicated in cases of hepatocellular adenoma <5 cm and an individualized approach is advocated for these patients (conditional recommendation, low quality of evidence).
10.	In hepatocellular adenoma ≥5 cm, intervention through surgical or nonsurgical modalities is recommended, as there is a risk of rupture and malignancy (conditional recommendation, low quality of evidence).
11.	If no therapeutic intervention is pursued, lesions suspected of being hepatocellular adenoma require follow-up CT or MRI at 6- to 12-month intervals. The duration of monitoring is based on the growth patterns and stability of the lesion over time (conditional recommendation, low quality of evidence).
Suspected hemangioma	
12.	An MRI or CT scan should be obtained to confirm a diagnosis of hemangioma (strong recommendation, moderate quality of evidence).
13.	Liver biopsy should be avoided if the radiologic features of a hemangioma are present (strong recommendation, low quality of evidence).
14.	Pregnancy and the use of oral contraceptives or anabolic steroids are not contraindicated in patients with a hemangioma (conditional recommendation, low quality of evidence).
15.	Regardless of the size, no intervention is required for asymptomatic hepatic hemangiomas. Symptomatic patients with impaired quality of life can be referred for surgical or nonsurgical therapeutic modalities by an experienced team (conditional recommendation, low quality of evidence).
Suspected focal nodular hyperplasia	
16.	An MRI or CT scan should be obtained to confirm a diagnosis of FNH. A liver biopsy is not routinely indicated to confirm the diagnosis (strong recommendation, low quality of evidence).
17.	Pregnancy and the use of oral contraceptives or anabolic steroids are not contraindicated in patients with FNH (conditional recommendation, low quality of evidence).
18.	Asymptomatic FNH does not require intervention (strong recommendation, moderate quality of evidence).
19.	Annual US for 2–3 years is prudent in women diagnosed with FNH who wish to continue OCP use. Individuals with a firm diagnosis of FNH who are not using OCP do not require follow-up imaging (conditional recommendation, low quality of evidence).
Suspected nodular regenerative hyperplasia	
20.	Liver biopsy is required to confirm the diagnosis of NRH (strong recommendation, moderate quality of evidence).
21.	Pregnancy and the use of oral contraceptives or anabolic steroids are not contraindicated in patients with an NRH (conditional recommendation, low quality of evidence).
22.	Asymptomatic NRH does not require intervention (conditional recommendation, low quality of evidence).
23.	Management of NRH is based on diagnosing and managing any underlying predisposing disease processes (strong recommendation, low quality of evidence).

Cystic FLL	
Suspect simple hepatic cysts	
24.	A hepatic cyst identified on US with septations, fenestrations, calcifications, irregular walls, or daughter cysts should prompt further evaluation with a CT or MRI (strong recommendation, low quality of evidence).
25.	Asymptomatic simple hepatic cysts should be observed with expectant management (strong recommendation, moderate quality of evidence).
26.	Aspiration of asymptomatic, simple hepatic cysts is not recommended (strong recommendation, low quality of evidence).
27.	Symptomatic simple hepatic cysts may be managed with laparoscopic deroofting rather than aspiration and sclerotherapy, dictated based on availability of local expertise (conditional recommendation, low quality of evidence).
Suspected biliary cystadenoma or cystadenocarcinoma	
28.	Routine fluid aspiration is not recommended when BCA is suspected because of limited sensitivity and the risk of malignant dissemination (strong recommendation, low quality of evidence).
29.	Imaging characteristics suggestive of BC or BCA, such as internal septations, fenestrations, calcifications, or irregular walls, should lead to referral for surgical excision (strong recommendation, low quality of evidence).
30.	Complete surgical excision, by an experienced team, is recommended if BC or BCA is suspected (strong recommendation, low quality of evidence).
Suspected polycystic liver disease	
31.	Routine medical therapy with mammalian target of rapamycin inhibitors or somatostatin analogs is not recommended (strong recommendation, low quality of evidence).
32.	Aspiration, deroofting, resection of a dominant cyst(s) can be performed based on the patient's clinical presentation and underlying hepatic reserve (conditional recommendation, low quality of evidence).
33.	Liver transplantation with or without kidney transplantation can be considered in patients with refractory symptoms and significant cyst burden (conditional recommendation, low quality of evidence).
Suspected hydatid cysts	
34.	MRI is preferred over CT for concomitant evaluation of the biliary tree and cystic contents (conditional recommendation, low quality of evidence).
35.	Monotherapy with anthelmintic drugs is not recommended in symptomatic patients who are surgical or percutaneous treatment candidates (strong recommendation, moderate quality of evidence).
36.	Adjunctive therapy with anthelmintic therapy is recommended in patients undergoing PAIR or surgery, and in those with peritoneal rupture or biliary rupture (strong recommendation, low quality of evidence).
37.	Percutaneous treatment with PAIR is recommended for patients with active hydatid cysts who are not surgical candidates, who decline surgery, or who relapse after surgery (strong recommendation, low quality of evidence).
38.	Surgery, either laparoscopic or open, based on available expertise, is recommended in complicated hydatid cysts with multiple vesicles, daughter cysts, fistulas, rupture, hemorrhage, or secondary infection (strong recommendation, low quality of evidence).


Marrero JA, Ahn J, Rajender Reddy K; American College of Gastroenterology. ACG clinical guideline: the diagnosis and management of focal liver lesions. *Am J Gastroenterol.* 2014 Sep;109(9):1328–47; quiz 1348. doi: 10.1038/ajg.2014.213. Epub 2014 Aug 19. PMID: 25135008.

—


Biliary leaks/bilomas

- Iatrogenic/non iatrogenic
- Iatrogenic after cholecystectomy or hepatic surgery
- Usually suspected clinically
- US, CT, MRCP are useful tools for diagnosis
- CE-MRI with hepatobiliary agents – hyperintense bile will extravasate outside the biliary tree/T1 hyperintense collections
- Additional delayed phases may be useful for detection (up to 180 min)

46, M, biliary leak visible on T1+C, hepatobiliary phase




60, M, biliary leak and biloma visible on T1+C, hepatobiliary phase




—

Assessment of liver function


Parameter	Explanation	Score
1- Graft Parenchymal Enhancement (EnQS)	SI graft parenchyma relative to kidney on HBP	0 Hypointense
		1 Isointense
		2 Hyperintense



Parameter	Explanation	Score
3- Portal Vein Sign (PVsQS)	PV SI relative to liver parenchyma SI on HBP	0 PV > Liver
		1 PV = Liver
		2 PV < Liver



Parameter	Explanation	Score
2- Contrast Excretion (ExQS)	CM in bile ducts on HBP	0 No biliary contrast excretion
		1 Excretion into peripheral IHD or RHD and/or LHD
		2 Excretion into the CHD, CBD or duodenum



Functional liver imaging score (FLIS)-Score


Poetter-Lang S, Bastati N, Messner A, Krstic A, Herold A, Hodge JC, Ba-Ssalamah A. Quantification of liver function using gadoteric acid-enhanced MRI. *Abdom Radiol (NY)*. 2020 Nov;45(11):3532-3544. doi: 10.1007/s00261-020-02779-x. Epub 2020 Oct 9. PMID: 33034671; PMCID: PMC7593310.

- Gadoteric acid is considered to be a noninvasive marker of hepatobiliary disorders
- NAFLD, fibrosis, cirrhosis, preoperative assessment
- FLIS score: parenchymal enhancement quality+ rate of biliary excretion + persistence of contrast in PV

—

Altered hepatic function

T₁+C, hepatobiliary





—

References

- Gatti M, Maino C, Tore D, Carisio A, Darvizeh F, Tricarico E, Inchingolo R, Ippolito D, Faletti R. Benign focal liver lesions: The role of magnetic resonance imaging. *World J Hepatol.* 2022 May 27;14(5):923-943. doi: 10.4254/wjh.v14.i5.923. PMID: 35721295; PMCID: PMC9157713.
- Francisco FA, de Araújo AL, Oliveira Neto JA, Parente DB. Hepatobiliary contrast agents: differential diagnosis of focal hepatic lesions, pitfalls and other indications. *Radiol Bras.* 2014 Sep-Oct;47(5):301-9. doi: 10.1590/0100-3984.2013.1867. PMID: 25741105; PMCID: PMC4341386.
- Morana G, Salvato E, Guarise A. Contrast agents for hepatic MRI. *Cancer Imaging.* 2007 Oct 1;7 Spec No A(Special issue A):S24-7. doi: 10.1102/1470-7330.2007.9001. PMID: 17921081; PMCID: PMC2727962.
- Thian YL, Riddell AM, Koh DM. Liver-specific agents for contrast-enhanced MRI: role in oncological imaging. *Cancer Imaging.* 2013 Dec 30;13(4):567-79. doi: 10.1102/1470-7330.2013.0050. PMID: 24434892; PMCID: PMC3893895.
- Xiao Y, Paudel R, Liu J, Ma C, Zhang Z and Zhou S: MRI contrast agents: Classification and application (Review). *Int J Mol Med* 38: 1319-1326, 2016
- Vernuccio, F., Gagliano, D.S., Cannella, R. et al. Spectrum of liver lesions hyperintense on hepatobiliary phase: an approach by clinical setting. *Insights Imaging* 12, 8 (2021). <https://doi.org/10.1186/s13244-020-00928-w>
- Ames JT, Federle MP, Chopra K. Distinguishing clinical and imaging features of nodular regenerative hyperplasia and large regenerative nodules of the liver. *Clin Radiol.* 2009 Dec;64(12):1190-5. doi: 10.1016/j.crad.2009.07.015. Epub 2009 Oct 8. PMID: 19913129.
- LeGout JD, Bolan CW, Bowman AW, Caserta MP, Chen FK, Cox KL, Sanyal R, Toskich BB, Lewis JT, Alexander LF. Focal Nodular Hyperplasia and Focal Nodular Hyperplasia-like Lesions. *Radiographics.* 2022 Jul-Aug;42(4):1043-1061. doi: 10.1148/rg.210156. Epub 2022 Jun 10. PMID: 35687520.
- Marrero JA, Ahn J, Rajender Reddy K; American College of Gastroenterology. ACG clinical guideline: the diagnosis and management of focal liver lesions. *Am J Gastroenterol.* 2014 Sep;109(9):1328-47; quiz 1348. doi: 10.1038/ajg.2014.213. Epub 2014 Aug 19. PMID: 25135008.
- Di Serafino M, Iacobellis F, Ronza R, Martino A, Grimaldi D, Rinaldo C, Caruso M, Dell'Aversano Orabona G, Barbuto L, Verde F, Sabatino V, Schillirò ML, Brillantino A, Romano L. Hepatobiliary-specific magnetic resonance contrast agents: role in biliary trauma. *Gland Surg.* 2023 Oct 30;12(10):1425-1433. doi: 10.21037/gs-23-29. Epub 2023 Oct 26. PMID: 38021201; PMCID: PMC10660186.
- Kul M, Erden A, Düşünceli Atman E. Diagnostic value of Gd-EOB-DTPA-enhanced MR cholangiography in non-invasive detection of postoperative bile leakage. *Br J Radiol.* 2017 Apr;90(1072):20160847. doi: 10.1259/bjr.20160847. Epub 2017 Feb 9. PMID: 28181823; PMCID: PMC5605073
- Poetter-Lang S, Bastati N, Messner A, Kristic A, Herold A, Hodge JC, Ba-Ssalamah A. Quantification of liver function using gadoteric acid-enhanced MRI. *Abdom Radiol (NY).* 2020 Nov;45(11):3532-3544. doi: 10.1007/s00261-020-02779-x. Epub 2020 Oct 9. PMID: 33034671; PMCID: PMC7593310.



Thank you!